Page 17 - Sylvia Wimmer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Heidelberg Pharma Expands Management Team
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Search jobs 11-Feb-2021 Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous
11.02.2021 / 07:58
PRESS RELEASE
Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in
Science Translational Medicine
- Extraordinary efficacy of a HER2-targeting Trastuzumab-ATAC in the treatment of Triple-Negative Breast Cancer (TNBC) with low HER2 expression and hemizygous deletion of chromosome 17p in preclinical models
- Induction of immunogenic cell death by an HER2-ATAC - Synergistic and increased efficacy in combination with checkpoint inhibitors
Heidelberg Pharma AG
DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Study
Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
04-Feb-2021 / 10:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement - Inside information pursuant to Article 17 MAR
FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Ladenburg, Germany, 4 February 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the US Food and Drug Administration (FDA) has informed the company it is safe to proceed with the Phase I/IIa study with the BCMA Antibody Targeted Amanitin Conjugate, HDP-101 that was submitted under its US IND. The study will evaluate HDP-101 for the treatment of multiple myeloma, a blood cancer
Search jobs 04-Feb-2021 Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Heidelberg Pharma AG / Key word(s): Study
Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
04-Feb-2021 / 10:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement - Inside information pursuant to Article 17 MAR
FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
vimarsana © 2020. All Rights Reserved.